T1	p 72 123	zoster vaccine in healthy adults ?60 years of age .
T2	p 161 176	herpes zoster (
T3	p 209 222	increase with
T4	p 227 228	,
T5	p 306 311	VZV )
T6	p 333 342	vaccine (
T7	p 507 547	with 210 subjects ?60 years old compared
T8	p 1674 1696	adults ?60 years old .
T9	i 298 305	virus (
T10	i 310 311	)
T11	i 343 347	ZV )
T12	i 448 450	ZV
T13	i 604 606	ZV
T14	i 636 643	placebo
T15	i 681 736	VZV interferon-gamma ( IFN-? ) enzyme-linked immunospot
T16	i 763 775	glycoprotein
T17	i 804 812	antibody
T18	i 823 824	)
T19	i 893 918	Vaccination Report Card .
T20	i 1019 1031	spot-forming
T21	i 1117 1121	16.9
T22	i 1304 1311	placebo
T23	i 1467 1469	ZV
T24	i 1500 1507	placebo
T25	i 1573 1580	ELISPOT
T26	i 1623 1625	ZV
T27	i 1714 1716	ZV
T28	i 1750 1768	boost VZV-specific
T29	o 6 48	Safety , tolerability , and immunogenicity
T30	o 149 179	severity of herpes zoster ( HZ
T31	o 269 277	immunity
T32	o 333 340	vaccine
T33	o 377 387	protection
T34	o 557 576	and safety profiles
T35	o 646 660	Immunogenicity
T36	o 685 709	interferon-gamma ( IFN-?
T37	o 737 754	( ELISPOT ) assay
T38	o 759 814	VZV glycoprotein enzyme-linked immunosorbent antibody (
T39	o 833 860	Adverse experiences ( AEs )
T40	o 930 957	serious vaccine-related AEs
T41	o 967 1041	. VZV IFN-? ELISPOT geometric mean count ( GMC ) of spot-forming cells per
T42	o 1051 1085	peripheral blood mononuclear cells
T43	o 1243 1248	, GMC
T44	o 1293 1296	GMC
T45	o 1356 1377	peak ELISPOT response
T46	o 1421 1462	gpELISA geometric mean titers ( GMTs ) in
T47	o 1563 1599	the IFN-? ELISPOT and gpELISA assays
T48	o 1640 1670	well-tolerated and immunogenic
T49	o 1714 1716	ZV
T50	o 1731 1735	safe
T51	o 1769 1777	immunity
T52	o 1785 1791	levels
T53	o 1801 1809	postdose